Giovedì 15 Novembre 2018 | 11:02

NEWS DALLA SEZIONE

Milan
People injured after Milan metro brakes hard

People injured after Milan metro brakes hard

 
Abu Dhabi
Conte meets Prince Nahyan in Abu Dhabi

Conte meets Prince Nahyan in Abu Dhabi

 
Sassari
Woman's funeral cancelled after untrue death report

Woman's funeral cancelled after untrue death report

 
Reggio Calabria
Thief nabbed after airport runway chase

Thief nabbed after airport runway chase

 
Vercelli
Not enough attention to Italian healthcare system-councillor

Not enough attention to Italian healthcare system-councillor

 
Milan
Leaguer acquitted for writing 'Come on Vesuvius'

Leaguer acquitted for writing 'Come on Vesuvius'

 
Sassari
Acquitted 26 years later, state to pay 63,000 in damages

Acquitted 26 years later, state to pay 63,000 in damages

 
Rome
X-Factor sensation Måneskin to make first European tour

X-Factor sensation Måneskin to make first European tour

 
Rome
Med diet theme for Italian Cuisine Week in World

Med diet theme for Italian Cuisine Week in World

 
Rome
Temperatures to drop 14 degrees by Monday

Temperatures to drop 14 degrees by Monday

 
Rome
Anti-migrant Leaguer voted head of human rights panel

Anti-migrant Leaguer voted head of human rights panel

 
Gazzettaffari - Portale di annunci de La Gazzetta del Mezzogiorno

Rome

Roche, Novartis CEOs risk trial for scorning drug (3)

Accused of share-rigging for denigrating Avastin

Roche, Novartis CEOs risk trial for scorning drug (3)

Rome, December 7 - The CEOs of Roche and Novartis risk trial in Italy for share-rigging over alleged denigratory campaign starting in 2011 against the eye-disease drug Avastin, prosecutors said Thursday. Roche's Maurizio De Cicco and Novartis's George Schrockn Fuchs received notification that a probe had ended, which is generally the prelude to an indictment request. The two managers are accused of conspiring to obstruct, via the diffusion of false news, the use of the very cheap Avastin in favour of a much dearer product, Lucentis. The two pharmaceutical giants were fined 180 million euros by Italian antitrust authorities for this affair. Rome prosecutors have based their case on the content of emails between De Cicco and Schrockn Fuchs. They are also relying on the results of a technical consultation which assessed the characteristics of the two products and their therapeutic efficacy.

Lascia il tuo commento

Condividi le tue opinioni su

Caratteri rimanenti: 400